Genetic polymorphisms and adverse effects that affect the natalizumab clinical response: a review
DOI:
https://doi.org/10.60988/p.v37i2S.282Keywords:
natalizumab; genetic polymorphisms; multiple sclerosis; mutations; responseAbstract
The clinical response to natalizumab in patients with multiple sclerosis (MS) may be significantly influenced by genetic variation. Mutations in genes related to the drug’s mechanism of action or the pathological milieu of MS can contribute substantially to interindividual differences in treatment outcomes. This review aims to provide an overview of previous studies that have examined genetic polymorphisms associated with the clinical efficacy of natalizumab. A systematic literature search was conducted across the PubMed, Google Scholar, and ResearchGate databases using targeted keywords relevant to the subject matter. Several genetic loci were found to be linked to natalizumab responsiveness, including the integrin subunit alpha 4 (ITGA4), the nicotinamide adenine dinucleotide phosphate (NADPH) quinone oxidoreductase 1 (NQO1), the glutathione S-transferase pi 1 (GSTP1), the glycoprotein VI platelet (GP6), and the alpha serine/threonine-protein kinase (AKT1) genes. Further research is warranted in order to explore the influence of genetic factors on treatment response across diverse populations. By synthesizing existing evidence, this review underscores the role of pharmacogenomics in optimizing the use of natalizumab and highlights its efficacy and safety in improving clinical outcomes.
References
1. García-Estévez D.A., Pérez-Lorenzo G., Fernández-Pérez M.J., Cid-Rodríguez C., Ozaita-Arteche G. Clinical and radiological effectiveness of natalizumab extended dosage interval in patients with relapsing multiple sclerosis. Rev. Neurol. 74(8), 265–268, 2022. DOI: 10.33588/rn.7408.2021311
2. Vermeire S. Biologic therapy of ulcerative colitis: natalizumab, vedolizumab, etrolizumab (rHUMab beta 7), anti-MAdCAM. In: Baumgart D. (editor). Crohn’s Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Second Edition. Cham: Springer, 449–454, 2017. DOI: 10.1007/978-3-319-33703-6_45
3. Ďurmanová V., Shawkatová I., Javor J., Párnická Z., Čopíková-Cundráková D., Turčáni P., et al. VLA4 gene polymorphism and susceptibility to multiple sclerosis in Slovaks. Folia Biol. (Praha) 61(1), 8–13, 2015. DOI: 10.14712/fb2015061010008
4. Ahmed F.T., Ali S.H., Al Gawwam G.A. Integrin alpha-4 gene polymorphism in relation to natalizumab response in multiple sclerosis patients. Neurol. Asia 28(2):349–358, 2023. DOI: 10.54029/2023afn
5. Khaliel A.H., Abbas A.A., Hatem A.O., Abdulamir A.S. The impact of very late antigen 4 polymorphism on drug responsiveness in patients with multiple sclerosis initiation. Iraqi J. Med. Sci. 20(1), 83–89, 2022. DOI: 10.22578/IJMS.20.1.11
6. Yu Y., Schürpf T., Springer T.A. How natalizumab binds and antagonizes α4 integrins. J. Biol. Chem. 288(45), 32314–32325, 2013. DOI: 10.1074/jbc.M113.501668
7. Ahmed F.T., Ali S.H., Al Gawwam G.A. Correlation between integrin alpha-4 gene polymorphisms and failure to respond to natalizumab therapy in Iraqi multiple sclerosis patients. Farmacia 71(3), 563–572, 2023. DOI: 10.31925/farmacia.2023.3.15
8. Alexoudi A., Zachaki S., Stavropoulou C., Gavrili S., Spiliopoulou C., Papadodima S., et al. Possible implication of GSTP1 and NQO1 polymorphisms on natalizumab response in multiple sclerosis. Ann. Clin. Lab. Sci. 46(6), 586–591, 2016.
9. Al-Mojel M., Alroughani R., Kannankeril T., Dashti M., Al-Temaimi R. GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients. Mult. Scler. Demyelinating Disord. 4, 2, 2019. DOI: 10.1186/s40893-019-0039-0
10. Rossi S., Motta C., Studer V., Monteleone F., De Chiara V., Buttari F., et al. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult. Scler. 19(1), 59–68, 2013. DOI: 10.1177/1352458512448106
